Suvendu Giri
Overview
Explore the profile of Suvendu Giri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Simoni-Nieves A, Lindzen M, Giri S, Gupta N, Chatterjee R, Selvadurai B, et al.
Cell Rep Med
. 2024 Aug;
5(9):101703.
PMID: 39216477
Activating EGFR (epidermal growth factor receptor) mutations can be inhibited by specific tyrosine kinase inhibitors (TKIs), which have changed the landscape of lung cancer therapy. However, due to secondary mutations...
2.
Marrocco I, Giri S, Simoni-Nieves A, Gupta N, Rudnitsky A, Haga Y, et al.
Cell Rep Med
. 2023 Aug;
4(8):101142.
PMID: 37557179
EGFR-specific tyrosine kinase inhibitors (TKIs), especially osimertinib, have changed lung cancer therapy, but secondary mutations confer drug resistance. Because other EGFR mutations promote dimerization-independent active conformations but L858R strictly depends...
3.
Ajaykumar A, Mathew A, Chandni A, Varma S, Jayaraj K, Sabira O, et al.
Antibiotics (Basel)
. 2023 Mar;
12(3).
PMID: 36978431
Silver nanoparticles (AgNPs) made by green synthesis offer a variety of biochemical properties and are an excellent alternative to traditional medications due to their low cost. In the current study,...
4.
Noronha A, Nataraj N, Lee J, Zhitomirsky B, Oren Y, Oster S, et al.
Cancer Discov
. 2022 Jul;
12(11):2666-2683.
PMID: 35895872
Significance: EGFR-mutant lung cancers treated with kinase inhibitors often evolve resistance due to secondary mutations. We report that in similarity to the bacterial SOS response stimulated by antibiotics, endogenous mutators...
5.
Giri S, Manivannan J, Srinivasan B, Sundaresan L, Gajalakshmi P, Chatterjee S
RSC Adv
. 2022 May;
8(36):20211-20221.
PMID: 35541641
Onco-cardiology is critical for the management of cancer therapeutics since many of the anti-cancer agents are associated with cardiotoxicity. Therefore, the major aim of the current study is to employ...
6.
Haga Y, Marrocco I, Noronha A, Uribe M, Nataraj N, Sekar A, et al.
Cancer Res
. 2021 May;
81(14):3862-3875.
PMID: 33941614
Lung cancers driven by mutant forms of EGFR invariably develop resistance to kinase inhibitors, often due to secondary mutations. Here we describe an unconventional mechanism of resistance to dacomitinib, a...
7.
Sundaresan L, Giri S, Singh H, Chatterjee S
Br J Clin Pharmacol
. 2021 Feb;
87(10):3835-3850.
PMID: 33609410
Aims: The SARS-coV-2 pandemic continues to cause an unprecedented global destabilization requiring urgent attention towards drug and vaccine development. Thalidomide, a drug with known anti-inflammatory and immunomodulatory effects has been...
8.
Giri S, Katakia Y, Chatterjee S, Gajalakshmi P
Clin Exp Pharmacol Physiol
. 2019 Sep;
47(1):7-15.
PMID: 31549415
Cardiovascular side effects of broadly used chemotherapeutic drugs such as Tamoxifen citrate (TC), Capecitabine (CP) and Epirubicin (EP) among cancer survivors are well established. Nitric oxide (NO) is known to...
9.
Banerjee S, Danielsson U, Dibitetto G, Giri S, Schillo M
Phys Rev Lett
. 2019 Jan;
121(26):261301.
PMID: 30636156
Recent developments in string compactifications demonstrate obstructions to the simplest constructions of low energy cosmologies with positive vacuum energy. The existence of obstacles to creating scale-separated de Sitter solutions indicates...
10.
Giri S, Bose J, Chandrasekar A, Tiwary B, Gajalakshmi P, Chatterjee S
Cardiovasc Toxicol
. 2018 Jul;
19(1):36-47.
PMID: 29974375
Chemotherapy induced cardiotoxicity leads to development of hypertension, conduction abnormalities, and congestive heart failure. However, there is no simple test to detect and assess cardiovascular risk in a chemotherapy treated...